Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule
作者： FRANK M. TORTI
DOI: 10.7326/0003-4819-99-6-745
关键词:
摘要: Abstract Endomyocardial biopsy was done 119 times in 98 patients receiving doxorubicin therapy once every 3 weeks and 41 27 weekly. Factors contributing to the degree of anthracycline-induced endomyocardial injury were evaluated. Neither age, sex, type malignancy, concomitant use other chemotherapeutic agents including cyclophosphamide, nor history cardiac disease or hypertension influenced extent injury. The dose (p = 0.0001) schedule (weekly versus weekly) 0.0020) independently predicted damage multivariate analyses. Previous irradiation had borderline significance 0.074) predicting this analysis. Doxorubicin administered on a weekly is associated with less than delivered conventional, 3-weekly schedule.
sci-hub.se 参考文章(16)
Daniel D Von Hoff, Maxwell W Layard, Peter Basa, HUGH L DAVIS Jr, Ann L Von Hoff, Marcel Rozencweig, Franco M Muggia, Risk Factors for Doxorubicin-lnduced Congestive Heart Failure Annals of Internal Medicine. ,vol. 91, pp. 710- 717 ,(1979) , 10.7326/0003-4819-91-5-710
Lawrence J. Ettinger, Harold O. Douglass, Donald J. Higby, Eugene R. Mindell, Freda Nime, Jaya Ghoorah, Arnold I. Freeman, Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma Cancer. ,vol. 47, pp. 248- 254 ,(1981) , 10.1002/1097-0142(19810115)47:2<248::AID-CNCR2820470208>3.0.CO;2-E
SEWA S. LEGHA, Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion Annals of Internal Medicine. ,vol. 96, pp. 133- 139 ,(1982) , 10.7326/0003-4819-96-2-133
Gianni Bonadonna, Roberto Zucali, Silvio Monfardini, Mario de Lena, Carlo Uslenghi, Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP Cancer. ,vol. 36, pp. 252- 259 ,(1975) , 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
Michael R. Bristow, Marcia B. Lopez, Jay W. Mason, Margaret E. Billingham, Mark A. Winchester, Efficacy and cost of cardiac monitoring in patients receiving doxorubicin Cancer. ,vol. 50, pp. 32- 41 ,(1982) , 10.1002/1097-0142(19820701)50:1<32::AID-CNCR2820500108>3.0.CO;2-Q
Arthur J. Weiss, Roland W. Manthel, Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer. ,vol. 40, pp. 2046- 2052 ,(1977) , 10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5
Jay W. Mason, Techniques for right and left ventricular endomyocardial biopsy American Journal of Cardiology. ,vol. 41, pp. 887- 892 ,(1978) , 10.1016/0002-9149(78)90729-4
Jonathan Alexander, Nicholas Dainiak, Harvey J. Berger, Lee Goldman, David Johnstone, Lawrence Reduto, Thomas Duffy, Peter Schwartz, Alexander Gottschalk, Barry L. Zaret, Linda Pytlik, Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography New England Journal of Medicine. ,vol. 300, pp. 278- 283 ,(1979) , 10.1056/NEJM197902083000603
MICHAEL R. BRISTOW, Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac Catheterization Annals of Internal Medicine. ,vol. 88, pp. 168- 175 ,(1978) , 10.7326/0003-4819-88-2-168
R. M. O'Bryan, L. H. Baker, J. E. Gottlieb, S. E. Rivkin, S. P. Balcerzak, G. N. Grumet, S. E. Salmon, T. E. Moon, B. Hoogstraten, Dose response evaluation of adriamycin in human neoplasia Cancer. ,vol. 39, pp. 1940- 1948 ,(1977) , 10.1002/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0